These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38805313)

  • 21. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
    Fenton MA; Tarantino P; Graff SL
    Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
    Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
    Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer.
    Al Jarroudi O; El Bairi K; Curigliano G; Afqir S
    Cancer Treat Res; 2023; 188():1-27. PubMed ID: 38175340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.
    Schwach J; Abdellatif M; Stengl A
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies.
    Kang X; Zhou L; Jian YM; Lan SA; Xu F
    Med Sci Monit; 2018 Mar; 24():1408-1416. PubMed ID: 29515096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-Drug Conjugates-A Tutorial Review.
    Baah S; Laws M; Rahman KM
    Molecules; 2021 May; 26(10):. PubMed ID: 34063364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
    Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.
    Rossi C; Chrétien ML; Casasnovas RO
    Target Oncol; 2018 Jun; 13(3):287-308. PubMed ID: 29556925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads.
    Boni V; Sharma MR; Patnaik A
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-17. PubMed ID: 32315240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody drug conjugates beyond cytotoxic payloads.
    Hobson AD
    Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The next generation of antibody drug conjugates.
    Mack F; Ritchie M; Sapra P
    Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
    Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
    Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
    Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
    Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
    Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
    Bosi C; Bartha Á; Galbardi B; Notini G; Naldini MM; Licata L; Viale G; Mariani M; Pistilli B; Ali HR; André F; Piras M; Callari M; Barreca M; Locatelli A; Viganò L; Criscitiello C; Pusztai L; Curigliano G; Győrffy B; Dugo M; Bianchini G
    Eur J Cancer; 2023 Dec; 195():113379. PubMed ID: 37913680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
    Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
    J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Loganzo F; Sung M; Gerber HP
    Mol Cancer Ther; 2016 Dec; 15(12):2825-2834. PubMed ID: 27780876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.